MIP Diagnostics continues 2021 success with ISO 9001 accreditation

Link to Full Article MIP Diagnostics, a UK manufacturer of molecularly imprinted polymers (MIPs) has achieved ISO 9001:2015 accreditation. MIP Diagnostics specialise in the development and manufacture of nanoscale molecularly imprinted polymers (nanoMIPs), which act as synthetic antibodies in diagnostic assays, sensors and other industry applications. After a strong start to 2021, MIP Diagnostics has […]

MIP Diagnostic Synthetic antibody offers ultra-high sensitivity for next wave of COVID-19 sensors

Link to Full Article MIP Diagnostics Ltd. has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices. nanoMIPs are nanoscale Molecularly Imprinted Polymers, commonly known as synthetic antibodies. They are manufactured around a template molecule […]

TECHNOLOGY MIP TECHNOLOGY OUR PUBLICATIONS APPLICATIONS SENSORS IVD ASSAYS SIMPLIFIED WORKFLOW PRODUCTS COVID-19 IN DEVELOPMENT SERVICES CUSTOM MIP DEVELOPMENT EPITOPE DISCOVERY RESOURCES NEWS EVENTS ABOUT ABOUT US BOARD OF DIRECTORS MANAGEMENT TEAM April 15, 2021 Mike Dalrymple joins MIP Diagnostics as Head of Global Business Development

Link to Full Article We are pleased to announce the appointment of Mike Dalrymple to the role of Head of Global Business Development at MIP Diagnostics on a consultancy basis. With over 30 years’ experience in diagnostics and therapeutics, Mike brings a wealth of knowledge and expertise to the business. Mike has a long track […]

Cynata Secures $15m Placement Led By $10M from Healthcare Investor BioScience Managers to Expand Development Pipeline

Melbourne, Australia; 11 December 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement (“Placement”), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate […]